Orion Pharma doses first patient in Phase 1/2 BICIDES trial of ODM-216 bispecific antibody in solid tumors
Bitget2026/10/05 12:04Orion launched a Phase 1/2 trial of ODM-216 in advanced solid tumors, marking first human dosing for its first biologic program. Results have not been presented; the study will generate initial safety, drug-behavior, and early anti-tumor activity readouts for future disclosure. Program targets two immune checkpoints, expanding the company’s immuno-oncology pipeline beyond its historical focus on small-molecule drugs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050800OMX_____CNEWS_EN_GNW1001276294_en) on October 05, 2026, and is solely responsible for the information contained therein.
- Orion launched a Phase 1/2 trial of ODM-216 in advanced solid tumors, marking first human dosing for its first biologic program.
- Results have not been presented; the study will generate initial safety, drug-behavior, and early anti-tumor activity readouts for future disclosure.
- Program targets two immune checkpoints, expanding the company’s immuno-oncology pipeline beyond its historical focus on small-molecule drugs.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
